Roche Diabetes Care expands exclusive distribution agreement with Senseonics for implantable Eversense CGM system

BASEL, Switzerland -- Roche has expanded its exclusive distribution agreement with Senseonics Holdings, Inc. Under the terms of the agreement, Roche will have exclusive rights to promote, market and sell the implantable Eversense CGM system across Europe, Middle East and Africa, excluding Scandinavia and Israel, while Senseonics will retain responsibility for product development, regulatory approval, quality management, and manufacturing.

The system will be made available to people with diabetes via clinics and medical practices that have been trained on the system. In May of this year, Roche had already signed an exclusive distribution agreement with Senseonics for its three pilot markets Germany, Italy and the Netherlands.

For more information, visit:

Suggested Articles

Hydrogen refueling stations are limited in the U.S., restricting interest in use of fuel cell electric cars

Silicon Labs is providing the BT module needed for detecting proximity with another Maggy device

Test automation won't fix everything, but can help, according to an automation engineer. Here are five problems to avoi to improve chances of success